Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sympathoinhibition as a Preferred Second Line Treatment of Obesity Related Hypertension

NCT04474899 is registered in ClinicalTrials.gov with Royal Perth Hospital as lead sponsor.

NCT NCT04474899
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04474899 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sympathoinhibition as a Preferred Second Line Treatment of Obesity Related Hypertension
Lead sponsor
Royal Perth Hospital
Phase
Phase 4
Overall status
Unknown status
Start date
June 24, 2015
Completion date
June 24, 2024
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension, obesity